NOHLA THERAPEUTICS
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
NOHLA THERAPEUTICS
Industry:
Biotechnology Health Diagnostics Therapeutics
Founded:
2015-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.nohlatherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
1(206)519-5300
Email Addresses:
[email protected]
Total Funding:
120.5 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS DigiCert SSL LiteSpeed Comcast Greenhouse MX
Current Employees Featured
Founder
Investors List
5AM Ventures
5AM Ventures investment in Series B - Nohla Therapeutics
Premier Partners
Premier Partners investment in Series B - Nohla Therapeutics
Alexandria Venture
Alexandria Venture investment in Series B - Nohla Therapeutics
Schroder Adveq
Schroder Adveq investment in Series B - Nohla Therapeutics
AML Biotech Partners
AML Biotech Partners investment in Series B - Nohla Therapeutics
UTEC - The University of Tokyo Edge Capital Partners
UTEC - The University of Tokyo Edge Capital Partners investment in Series B - Nohla Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Nohla Therapeutics
Celgene
Celgene investment in Series B - Nohla Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Nohla Therapeutics
5AM Ventures
5AM Ventures investment in Series B - Nohla Therapeutics
Official Site Inspections
http://www.nohlatherapeutics.com
- Host name: 104.255.193.170.static.supercp.com
- IP address: 104.255.193.170
- Location: Ann Arbor United States
- Latitude: 42.2503
- Longitude: -83.8393
- Metro Code: 505
- Timezone: America/Detroit
- Postal: 48106
More informations about "Nohla Therapeutics"
Nohla Therapeutics - Crunchbase Company Profile
Nohla Therapeutics is a biotechnology company that develops a shelf alternative to bone marrow transplants. View contacts for Nohla Therapeutics to access new leads and connect with decision-makers.See details»
Nohla Therapeutics - LinkedIn
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy...See details»
Nohla Therapeutics - PitchBook
Developer of universal, off-the-shelf cell therapies intended to help treat hematologic malignancies and other critical diseases.See details»
Nohla Therapeutics - Craft
See insights on Nohla Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Nohla Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Nohla Therapeutics Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
FDA Grants Fast Track Designation to Dilanubicel for …
Aug 6, 2018 · The FDA has granted a fast track designation to Nohla Therapeutics’ dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant.See details»
NOHLA THERAPEUTICS LAUNCHES WITH MAJOR US CANCER …
Dec 3, 2015 · Nohla Therapeutics Inc. (Nohla), a new cellular therapies start-up based in Seattle, Washington, is pleased to announce the signing of an exclusive licensing and collaboration …See details»
Nohla Therapeutics Announces Second Closing of $56 Million
Nov 7, 2018 · Nohla Therapeutics is a leading developer of universal, off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla’s proprietary notch ligand technology …See details»
Nohla Therapeutics Selects Advanced Therapies Business Unit of …
Mar 26, 2018 · SEATTLE & PHILADELPHIA— (BUSINESS WIRE)—Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignancies …See details»
Nohla Therapeutics Information - RocketReach
Nohla Therapeutics is a Biotechnology, Pharmaceuticals, and Science and Engineering company_reader located in Seattle, Washington with $9.8 million in revenue and 29 …See details»
Startup Nohla Therapeutics to build on Hutch cord-blood work
Dec 3, 2015 · With decades of research and a handful of successful clinical trials behind it, a biotechnology startup is launching Thursday to work on improving the use of umbilical-cord …See details»
Nohla Therapeutics Selects Advanced Therapies Business Unit of …
Mar 21, 2018 · Nohla Therapeutics is a clinical stage cell therapy company that’s redefining clinical outcomes for patients with critical diseases by providing a short-term hematopoietic …See details»
Nohla Therapeutics Announces Closing of $45 Million Series
SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other …See details»
Nohla Therapeutics Receives FDA Orphan Drug Designation for
Jul 16, 2018 · Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla’s proprietary notch ligand technology platform …See details»
Nohla Therapeutics Launches with Major US Cancer Research …
Dec 3, 2015 · SEATTLE-- ( BUSINESS WIRE )--Nohla Therapeutics Inc. (Nohla), a new cellular therapies start-up based in Seattle, Washington, is pleased to announce the signing of an …See details»
Nohla Therapeutics Management Team | Org Chart - RocketReach
The Nohla Therapeutics management team includes Tom Swallow (Vice President, Finance and Administration), Emily Cox (Clinical Research Associate), and Nohla Therapeutics (Nohla …See details»
Nohla Announces EHA Abstract Acceptance on Dilanubicel
May 17, 2018 · The abstract summarizes long-term follow-up data showing that Nohla’s dilanubicel (NLA101) cell therapy significantly improved hematopoietic recovery with no …See details»
Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of
Feb 13, 2018 · Nohla Therapeutics is a clinical stage cell therapy company that’s redefining clinical outcomes for patients with critical diseases by providing a short-term hematopoietic …See details»
Working at Nohla Therapeutics - Glassdoor
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other …See details»
Nohla Therapeutics Announces Closing of $43.5M Series A
Nov 29, 2016 · Nohla Therapeutics Inc. (Nohla) is a clinical stage developer of universal donor cellular therapies for the treatment of patients with life threatening hematological disorders.See details»